Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Shenghuo to Restate Financial Results

publication date: Aug 20, 2008

China Shenghuo Pharmaceutical Holdings, Inc. will restate its financial reports from the past twelve months, saying that the company has discovered errors in sales commission advances and trade receivables. The Audit Committee and an independent counsel will review Shenghuo’s internal controls and the personnel who are involved. The company did not hint at the magnitude of the restatement, though it does expect to complete the review and present restated results within two months. More details...

Stock Symbol: (AMEX: KUN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital